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Luca Borradori and Christoph Schlapbach*
Department of Dermatology, Inselspital-Bern University Hospital, University of Bern, Bern, Switzerland
Recent studies suggest an important role of immunoglobulin E (IgE) as an alternative
pathogenic pathway in the development of bullous pemphigoid (BP), as themost frequent
subepidermal blistering disease of the skin Use of IgE targeted therapies, such as
omalizumab, has been shown promising in recent studies. The aim of this study was
to assess the effect of omalizumab on FcεRI and IgE expression on circulating basophils
and on lesional intradermal cells in BP to generate insight into the immunological effects of
omalizumab in BP. We report two cases of BP patients treated with omalizumab. Efficacy
of treatment was assessed clinically 4 months after initiation of the therapy. Lesional and
non-lesional skin biopsies where taken before and 4 weeks after initiation of omalizumab
therapy. In addition, FcεRI expression on circulating cells and IgE levels in serum and in
the skin samples, as well as anti-BP180 and anti-BP230 in serum and eosinophils and
basophils counts in blood were assessed before and during treatment. Both patients
showed amarked improvement after 4 months, with no adverse effects. Down-regulation
of FcεRI, IgE in lesional skin and on circulating basophils were observed in parallel
with clinical improvement. The current case study supports the role of omalizumab in
the treatment of a subset of BP patients. Our observations suggest that omalizumab
represents a valuable therapeutic option in the management of BP patients. Its efficacy
might be related to reduction in FcεRI+ and IgE+ basophils and intradermal cells.
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INTRODUCTION
Bullous pemphigoid (BP) is a blistering antibody-mediated autoimmune skin disease. BP is
associated with tissue-bound and circulating autoantibodies directed against two hemidesmosomal
proteins, BP180 (also called BPAG2, type XVII collagen) and/or BP230 (also called BPAG1-e)
(1, 2). For many decades, studies examining the pathogenic mechanisms of BP autoantibodies
focused solely on IgG (3). In recent years, presence of IgE antibodies against the basement
membrane zone components, elevated serum IgE and BP180-specific IgE in BP sera suggested
that IgE has a role in BP pathogenesis (1–14). As a result, humanized monoclonal antibody
directed to IgE, omalizumab, an approved treatment for severe asthma and chronic spontaneous
urticaria, might represent an alternative drug for BP. Although the clinical effectiveness
of omalizumab in treatment of BP has been already demonstrated (1, 2, 12, 15–18), the
exact mechanism of action remains elusive. Furthermore, current data suggest that only
a subset of BP patients respond favorably to omalizumab treatment. However, biomarkers
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TABLE 1 | Patients characteristics.
Patient
no.
Age
(range)
Diagnosis of BP Previous Therapies Before Therapy
assessments
Therapy regime After Therapy assessments Clinical response
1 60–65 - Intense pruritus, blisters
since 2 years
- Subepidermal blister in
histological examination of
the lesional skin
- Linear deposits of IgG and
complement C3 at the
dermal-epidermal junction
in direct
immunofluorescence of
lesional/perilesional skin
- Topical corticosteroid
- Systemic
corticosteroids
- Azathioprine
- Tetracycline/nicotinamide
- Serum level of IgE
(1,176 U/L) and
basophil membrane
FcεRI (42′778)
- Eosinophilia (0.62
G/L)
- Circulating IgG
antibodies against
BP-180 (45 U/L) and
BP-230 (106 U/L)
- Normal
basophil count
- 300mg subcutaneously
every 2 weeks initially for
the first month in
combination with topical
steroid and then in
monthly regime
in monotherapy
- Immunohistochemical analysis of
the skin biopsy, showed a notable
decrease in the tissue FcεRI+ and
IgE+ cells after 4 weeks of the
treatment
- Decreased basophil-membrane
FcεRI (3′632 after 1 month; 3′063
after 4 months of the treatment)
- Serum total IgE during treatment
showed an increase after 1 month
to 1,843 U/L with further relative
decrease after 4 months (1,466
U/L) and increase after 6 months
(2202 U/L).
- Circulating IgG antibodies against
BP-180 (21.3 U/L) and BP-230
(97.3 U/L) after 6 months
- Eosinophil count decreased after 4
weeks of treatment (0.22 G/L).
- After 4 months of
therapy the patient’s
skin was clinically
disease-free and
pruritus subsided
completely.
- No adverse events
were reported.
2 70–75 - A long history of itchy
dermatosis without
blisters
- Subepidermal blister with
an eosinophil-rich
inflammation in
histological examination of
the lesional skin
- Linear deposits of IgG, IgE
and C3 at the
dermal-epidermal junction
in direct
immunofluorescence of
perilesional skin
- Topical corticosteroid
- Systemic corticosteroids
- Serum level of IgE
(410 U/L) and
basophil membrane
FcεRI (97′201).
- Normal eosinophil
count (0.34 G/L)
- Circulating IgG
antibodies against
BP-180 (21.7 U/L)
and BP-230 (11.5
U/L)
- Normal
basophil count
300mg subcutaneously
monthly, initially in
combination with topical
steroid and then in
monotherapy
- Immunohistochemical analysis of
the skin biopsy, showed a notable
decrease in the tissue FcεRI+ and
IgE+ cells after 4 weeks of the
treatment
- Decreased basophil-membrane
FcεRI [3′678 after 1 month,
remained low after 5 months of
treatment (6′367)].
- Serum total IgE during treatment
showed a slight increase after 1
month to 553 U/L with further
values fluctuating between 650 and
730 U/L in the following months.
- Circulating IgG antibodies against
BP-180 (17.9 U/L) and BP-230 (7.3
U/L) after 6 months
- Basophils granulocytes remained
low during treatment
- Eosinophil counts slightly increased
(0.37 after 1 month, 0.83 after
4 months).
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to identify the subset of BP that profits from anti-IgE treatment
have yet to be identified (19). In chronic spontaneous urticaria,
changes in serum IgE levels and in FcεRI expression on basophils
post anti-IgE therapy have been linked to therapy success. We
aimed therefore in this study to assess the effect of omalizumab
on FcεRI and IgE expression on circulating basophils and on
lesional intradermal cells in BP to generate insight into the
immunological effects of omalizumab in BP.
REPORT OF THE CASES
Two patients with severe recalcitrant BP treated with
omalizumab at Department of Dermatology, Bern University
Hospital were included after informed consent. Both patients
have suffered from intense pruritus since long time. The previous
standard local and systemic therapies could not improve
their complaints.
Efficacy of treatment was assessed clinically 4 months after
initiation of the therapy. Lesional and non-lesional skin biopsies
where taken before and 4 weeks after initiation of omalizumab
therapy. In addition, FcεRI expression on circulating cells and
IgE levels in serum and in the skin samples, as well as anti-
BP180 and -BP230 in serum, eosinophils and basophils counts
in blood were assessed before and during treatment, as discussed
before (20, 21).
After 4 months of therapy (300mg subcutaneously every 4
weeks), the patients were clinically disease-free and the pruritus
subsided completely. The patients did not report any adverse
events (Table 1, Figure 1).
The eosinophils, basophils and IgE level in serum were
variably affected and differed between the two patients. The
BP-180/230 level decreased also slightly in our patients under
Therapy. However, levels of FcεRI on circulating basophils
decreased dramatically. Furthermore, a significant reduction
of IgE+ and FcεRI+ cells in dermis were observed in the
immunohistochemistry stainings after 4 weeks of omalizumab
treatment (Figures 2, 3). To investigate the cellular source of
FcεRI-carrying cells, we performed double immunofluorescence
in lesional skin for markers of mast cells (tryptase) and antigen
FIGURE 1 | Clinical evaluation before (left), 10 days after (middle) and 4 months after the therapy in the first patient.
presenting cells (CD163) together with FcεRI staining. Both
mast cells and APCs were found to express FcεRI in lesional
skin (Figure 3).
DISCUSSION
Our study in two patients with therapy-resistant BP in which
omalizumab was used as rescue therapy has assessed the impact
of omalizumab on levels of eosinophils, basophils, and IgE in
the circulation, on FcεRI expression on circulating basophils, and
on lesional expression of IgE and FcεRI in skin biopsy samples.
Our observations suggest that changes in lesional IgE and FcεRI
expressionmight be useful to distinguish the subset of BP patients
who benefit from omalizumab therapy.
Frequent detection of high levels of IgE autoantibodies against
BP180 and BP230, increased serum levels of IgE and the reported
beneficial effect of anti-IgE therapy in small case series support
the idea that IgE autoantibodies are involved in BP pathogenesis
(1, 2, 5, 10, 12, 15–18, 22–24). However, the pathogenicity of
IgE autoantibody in BP remains unclear (25). It is thought that
IgE autoantibodies directed against the extracellular domain of
BP180 are first bound to FcεRI on mast cells and eosinophils.
This binding subsequently promotes degranulation and initiates
an inflammatory reaction resulting in further tissue damage
and blister formation (2, 12, 26). In addition, binding of
specific IgE autoantibodies to the ectodomain of BP180 on
basal keratinocytes may lead to internalization of BP180 and
thereby contribute to cell-substrate dysadesion and blister
formation (2, 12, 16).
Recent studies found that high serum levels of IgE correlate
with disease severity in BP. In our two cases, however, there was
no reduction of serum IgE levels 4 months after omalizumab
therapy compared to baseline, despite clinical remission. It is
conceivable that omalizumab, although it did not reduce the total
IgE serum levels in our patients, is able to sequester free IgE
and prevent its binding to its high-affinity IgE receptor, FcεRI
(7, 27, 28). This process has been proposed to then down-regulate
the expression of FcεRI on mast cells and basophils as well as
antigen-presenting cells (7). In addition to its ability to neutralize
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the free IgE, omalizumab causes dissociation of IgE from the
IgE-FcεRI complex (27, 28). IgE-free FcεRI is unstable and is
then internalized for degradation. By this means, the activation of
mast cells and basophils is reduced (7, 27–29). In line with these
hypotheses, we found a sharp decrease of FcεRI expression on
circulating basophils and a strong reduction of FcεRI+ cells in
the skin of both patients after 4 weeks of omalizumab treatment
(Figures 2, 3). These events might consequently lead to local
FIGURE 2 | Despite therapy with omalizumab the eosinophils and basophils increased during therapy in the second patient. IgE level in serum did not also decrease.
However, serum level of FcεRI decreased dramatically.
FIGURE 3 | (A,B) Significant reduction of IgE+ and FcεRI+ cells in dermis in the immunohistochemistry stainings of the patients after 4 weeks of omalizumab
treatment. (C) Both mast cells and APCs were found to express FcεRI in lesional skin (arrows show double positive cells).
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depletion of IgE, as reflected by a strong reduction of IgE+ cells
in dermis of both our patients after 4 weeks of omalizumab
treatment. Interestingly, Metz et al. showed in a similar study that
clinical efficacy of omalizumab in chronic spontaneous urticaria
is associated with decreases in FcεRI+ cells and IgE+ cells in
lesional and non-lesional skin (dermis) of patients (to levels seen
in healthy subjects) (30).
BP180 and BP230 ELISAs are highly sensitive methods for
the diagnosis of BP, in particular BP180 ELISA, is a sensitive
tool for monitoring disease activity (31–33). However, in our
patients no decrease in the level of specific IgG BP180 and
BP230 autoantibodies was observed after 4 months, despite
marked clinical improvement. In line with this observation,
Balakirski et al. reported no changes in circulating autoantibodies
within 6 months after the treatment with omalizumab (16).
Similarly, Yu et al. noticed only gradual decline in the level
of these antibodies in 6 BP patients treated with omalizumab
(23). It is thus possible that in a subset of BP patients,
disease activity is not entirely driven by BP180/230-specific
IgG antibodies but that IgE autoantibodies also substantially
contribute to disease. It is tempting to speculate that these BP
patients might represent the subset most likely to respond to
anti-IgE treatment. Further studies are needed to investigate
this hypothesis. Peripheral eosinophilia has been reported in
50–70% of BP patients (3, 22, 34–37). de Graauw et al.
demonstrated that IL-5-activated eosinophils directly contribute
to BP blister formation in the presence of BP autoantibodies.
Dermal–epidermal separation by IL-5-activated eosinophils
depends on adhesion and Fcγ receptor activation, requires
elevated reactive oxygen species production, degranulation and
involves eosinophil extracellular trap formation (38). It has
recently been shown that peripheral eosinophilia correlated
with the overall disease activity and the extent of erosions and
blisters (3). Interestingly, our second patient did not have an
elevated eosinophil count before treatment but showed rapid
clinical improvement suggesting that peripheral eosinophilia
might not serve as biomarker for response to omalizumab.
In contrast, it has been claimed that asthma patients with
a higher baseline peripheral eosinophil count show a better
clinical outcome after omalizumab (39). To what extent the
mechanisms of action of omalizumab is shared between BP,
allergic asthma, and chronic spontaneous urticaria remains to
be elucidated.
Our findings support the idea that IgE autoantibodies
contribute to tissue damage. Prospective, randomized controlled
trials are necessary to confirm that omalizumab represents a
new treatment option for BP. However, the current literature
suggests that only a subset of patients responds to omalizumab
therapy. Therefore, it is paramount to identify biomarkers
that predict the best treatment for the individual BP patient.
Biomarker development typically relies on a solid understanding
of the pathomechanisms at play. In this context, the exact
mechanisms by which IgE contributes to pathogenesis in BP
is not completely clear. Our data now suggests that optimal
clinical responses to anti-IgE treatment in BPmight be associated
with dissociation of the IgE-FcεRI complex, consecutive down-
regulation of FcεRI expression, and finally a decrease in lesional
IgE-bearing immune cells. These observations provide novel
insight into the immunomodulatory effects at the tissue level
of anti-IgE treatment in BP and lay an important basis for
future studies.
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